Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin Drug-Drug Interaction Study in Healthy Volunteers
NCT03411122Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin in cancer, sponsored by Sumitomo Pharma America. Primary endpoints: Pharmacokinetics of napabucasin at 7 days and Pharmacokinetics of CYP450 probe drugs and BCRP substrate at 7 days. Started Jun 2017; status: completed.
02
Drugs
napabucasin
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03411122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411122.